Medtronic Advances Hugo RAS System into General Surgery and Gynecology, Challenging da Vinci's Core Markets

Source:MedRobot

Reposting Requirements: Direct reposting is permitted; please cite the source at the beginning of the article.

June 3, 2026,Medtronic（NYSE: MDT）Release of Financial Report for the Fourth Quarter of Fiscal Year 2026, with Revenue Reaching$9.807 billion, year-on-year increase9.9%，Exceeding Wall Street Expectations$9.61 billion; Adjusted earnings per share$1.55，In line with market expectations. This figure marks Medtronic’s achievement ofStrongest Annual Revenue Growth in a Decade。

CEO Geoff Marthastated bluntly during the earnings conference call:"These results reflect the cumulative effect of our prudent decisions in strengthening strategy, enhancing execution capabilities, and investing in areas that drive future growth."

Medtronic's stock price rose more than on the day of the earnings release5%to $77.67, while the S&P 500 Index edged down during the same period. Needham & Co. analyst Mike Matson maintained a "Buy" rating, stating that "Medtronic is in the early stages of a strong product cycle, with improved growth in F4Q26 supporting this view."

# Hugo Robot’s US Expansion: A “Three-Step” Strategy from Urology to General Surgery and Gynecology

Alongside its financial report, Medtronic disclosed progress on the expansion of multiple indications for the Hugo™ Robot-Assisted Surgery (RAS) System in the United States:

Key Background:

The Hugo system received FDA approval for urological surgery in December 2025, having previously beenMore than 35 countriesCommercial operations for nearly five years, with a cumulative completion ofTens of Thousands of Surgeries, and haveHundreds of independently published scientific papersSupports its safety and efficacy.

The 510(k) submissions for General Surgery and Gynecology filed this time represent a conventional pathway for introducing indications already approved overseas to the U.S. market. Both departments areHigh-Volume Surgical Specialty, also Intuitive Surgical's da Vinci (da Vinci) core areas that have been dominated by the system for a long time.

Product Ecosystem Synergy:

• ProGrip Advanced Mesh: Specifically designed for robot-assisted abdominal wall hernia repair, the cumulative usage of the ProGrip series has exceeded6 million cases. Approximately ... in the United States each year470,000 casesAbdominal wall hernia repair surgery, increasingly shifting to ambulatory surgery centers (ASCs).

• LigaSure RAS Maryland: Specifically designed for use with the Valleylab FT10 energy platform on Hugo, LigaSure technology has been used globally over35 million cases. The deep integration of energy devices with robotic platforms is a key dimension of competition in the current surgical robot ecosystem.

Clinical Data Support:

The Embrace Gynecological IDE Study is a prospective, multicenter study in the United StatesFive HospitalsEnrollment70 Patients, enrollment has been completed. The study results will support the clinical data package for the gynecological 510(k) submission.

# Impact on Industry Landscape: Is the "One Superpower, Multiple Strong Competitors" Structure of Surgical Robots Facing Restructuring?

From an industry observation perspective, Medtronic’s concentrated push to expand Hugo’s indications across multiple specialties sends several key signals:

1. Competition in Soft-Tissue Surgical Robots Enters the "Ecosystem War" Phase

Intuitive’s da Vinci system has established years of FDA-approved indications and a mature installed base in general surgery and gynecology in the United States, but Hugo’s differentiated path lies in"Platform + Energy + Consumables" Integrated Ecosystem. The deep integration of the LigaSure energy platform with Hugo signifies that Medtronic is replicating its successful “energy devices + platform” model from open and laparoscopic surgeries.

2. The ASC Scenario Becomes a New Battlefield

ProGrip Advanced mesh is designed for abdominal wall hernia repair, while there is a clear trend of hernia repair surgeries shifting to Ambulatory Surgery Centers (ASCs). If Hugo gains approval in general surgery, it will directly enter this growing market and compete head-to-head with da Vinci in the ASC setting.

3. Approval Pace Determines the Commercialization Window for Fiscal Year 2026

The FDA 510(k) approval timelines for general surgery and gynecology, along with the completion of follow-up and formation of the data package from the Embrace study, will directly determine whether Hugo can complete its multi-specialty commercial launch in the U.S. market within fiscal year 2026. If approvals proceed smoothly, Hugo is poised to become a key growth engine for Medtronic’s Medical Surgical portfolio in fiscal year 2027.

# Conclusion

Medtronic’s strongest growth in a decade in Q4 was not an accidental surge driven by a single product, but rather"Strategic Focus + Product Cycle + Operational Execution"The combined effect of three factors.PFA ablation business, with a 78% global growth rate, has validated its disruptive potential in the electrophysiology field, while the expansion of the Hugo robot from urology to general surgery and gynecology marks Medtronic's formal challenge to Intuitive's dominance in the soft tissue surgical robotics sector.

For industry observers, the period from the second half of 2026 to the first half of 2027 will be a critical window: the EU market launch and progress of pivotal US trials for Affera Sphere-360, FDA approval outcomes for Hugo’s two 510(k) submissions, and the integration pace of the ICE ecosystem will collectively determine whether Medtronic can transform its “strongest growth in a decade” from a single-quarter highlight into a sustainable structural advantage.